12globeM

China Updates: China’s PMIs entered the contraction zone as Covid-19 cases resurged

Macro

Summary:  China’s March PMIs showed across the board weaknesses in the economy’s manufacturing activities, new export orders and the service sector. Moreover, resurgence of Covid-19 cases, particularly in major cities such as Shanghai, is dampening China's growth outlook further. According to economists’ estimates, imposing lockdown for half-a-month on Shanghai will knock 4% off China’s GDP during that half-a-month. This translates into a decline in annual national GDP by approximately 0.17%.


March PMIs signaled widespread deceleration in economic activities. China released its March PMI data with across the board weaknesses.  Both Manufacturing and non-manufacturing PMIs fell below 50, the expansion-contraction threshold, to 49.5 (vs 50.2 in Feb.) and 48.4 (vs 51.6 in Feb.) respectively and below already subdue expectations.  Most sub-indices fell from last month and went below 50.  New orders came at 47.2 (vs 49 in Feb.).  Employment and raw materials inventory were down to 48.6 (vs 49.2 in Feb.) and 47.3 (vs 48.1 in Feb) respectively.  Services fell sharply to 46.7 (vs 50.5 in Feb) as this sector was most affected by the Covid related lockdowns and other restrictions on mobility of people.  The only bright spot was construction which is a sub-index under non-manufacturing.  The strength in construction mainly came from infrastructure related construction works.  Separately, the Caixin China PMI Manufacturing, which focused on private industrial companies, also fell to 48.1 in March (vs 50.4 in February).

Exports are not going to help in 2022.  PMI’s New export orders sub-index was 47.2 (vs 49.0 in February).  This, taking together with the negative growth in throughput in the eight largest ports in China recently and declines in China to Europe and the U.S. West coast container freight rates, it is fair to expect that exports, last year’s GDP key growth driver, are set to lose momentum and decelerate in growth. 

Resurgence of Covid-19 outbreaks contributed to the weakness in economic activities .  In China, excluding Hong Kong, the total number of local Covid-19 cases has been subdue over a long period of time unitl February 2022 with the highest daily new cases, including symptomatic and asymptomatic cases, being 223 on Jan 20, 2021.  However, the total number of new cases rose to 505 on March 7, 2022 and then continued to surge exponentially to 8,454 on Mar 30, 2022. These cases spread over 54 high-risk districts and 474 medium-risk districts in 15 provinces, two municipalities and one autonomous region. 

High-risk districts are districts that have more than 50 cumulative cases and a cluster of epidemics occurred in the last 14 days. Medium-risk districts are districts that have newly confirmed cases in the last 14 days but the cumulative number of confirmed cases does not exceed 50, or districts that have cumulative number of confirmed cases exceeding 50 but no cluster of epidemics occurred in the last 14 days.  According to Goldman Sachs’ estimates, cities with high-risk districts accounted for about 10% of China’s national GDP and cities with medium-risk districts represented 20% of national GDP.  Covid related mobility restrictions or even lockdowns in these districts have significantly affected economic activities. 

Expecting lockdowns as Covid outbreaks persist. Ahead of the Chinese Communist Party’s all important 20th Party Congress that is going to determine the leadership in the next five or even 10 years, large-scale Covid infection and mortality are simply unacceptable and out of the question for the Chinese authorities.  As discussed in our previous note, China prides its effective administration of the “zero-Covid approach” for the Chinese economy’s impressive rebound from the pandemic before everyone else in 2021.  It has been advocating to the country’s population as well as the rest of the world that this success as demonstration of President’s Xi’s socialism with Chinese characteristics for a new era. Although Xi Jinping said that “more effective measures should be taken to achieve maximum effect in prevention and control with minimum cost, and to reduce the impact on socioeconomic development as much as possible” in a meeting of the Central Committee of the Chinese Communist Party’s Politburo on March 17, 2022, it is unlikely for abandonment of the “dynamic zero-Covid” approach to happen and lockdowns are still to be expected when outbreaks persist. 

Recent and future lockdowns will make China’s 5.5% GDP growth target for 2022 a huge challenge. Of the 8,454 cases on Mar 30, 2022, 5,301 cases or 62.7% are in Shanghai.  It is worth to note that the March PMI survey took place before the staggered lockdown of Shanghai for mass Covid tests started on March 28, 2022.  It is likely that the April PMI, once having taken in the full impact of the more recent surge of cases and the Shanghai staggered lockdown, will decelerate further.  During the lockdown, many factories have suspended production, including Tesla’s plant in Shanghai. The mobility of people came to a halt and trucking capacity was reportedly cut by 30%.  According to Nomura Securities, Maersk, the Danish container shipping giant, has closed its counter office and all of its warehouses in Shanghai from March 28, 2022 and the number of cargo ships queuing outside of the ports in Shanghai and nearby Ningbo have increased from 120 vessels to 168 as of March 30, 2022.  

A recent economic research paper (Chen et al, 2022) uses historical data of changes in truck flows from 16 whole-city lockdowns and 18 partial (i.e. only some but not all counties/districts in a city) lockdowns in Chinese cities to estimate the economic cost of lockdown in China. Its findings suggest that the imposition of a full-scale lockdown for half-a-month on Shanghai will knock 4% off China’s GDP during that half-a-month.  This implies a decline in annual national GDP by approximately 0.17%.  It is also estimated that imposing one-month full-scale lockdown on China’s four largest 4 cities (Beijing, Guangzhou, Shanghai and Shenzhen) at the same time, the four cities will lose their real income by 61% for that month and the national GDP would fall by 12% for that month or approximately 1% for the year. This estimated cost is substantially higher than the 1% national annual GDP loss from a 4-week lockdown of all the high-risk and medium risk districts being put forwarded by Goldman Sachs.   Escalation of lockdowns will be costly and make China’s 5.5% GDP growth target increasingly challenging. 

COVID U Index China Local Covi 20220401 000655
Source: Saxo Markets, Bloomberg LP

Disclaimer

Confidentiality and Usage:
You may not reproduce, distribute, or transmit this material or any portion thereof without prior written permission from Saxo.

Nature of Information:
The information provided herein is based on current market conditions and analysts' opinions, which may reflect personal views of the author, and are subject to change without notice. This material does not include a record of any trading prices, or an offer of, or solicitation for, or endorsement to enter into any transaction in any investment product. Any forecast on the economy, markets and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the investment product subject of this material.

Responsibility and Liability:
Saxo accepts no liability for any use that may be made of these comments or for any consequences that arise from such use. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

The information provided in this material is solely for information only. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning specific situations of any person. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase an investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether any investment product mentioned in this publication is suitable for you.

Notwithstanding the above, insofar as any information provided herein contains research analyses or reports concerning any investment product authored by any foreign research house and is issued or promulgated to a person in Singapore who is not an accredited investor, expert investor, and/or institutional investor, Saxo Capital Market Pte. Ltd. accepts legal responsibility for the contents of this material to the extent required by law. Recipients of such material are to contact Saxo Capital Markets Pte. Ltd. in respect of any matters arising from, or in connection with, this material.

Risk Disclosure:
Trading in investment products involve significant risk, including the risk of losing your entire investment. Historical returns are not a guarantee of future returns. Prices can both rise and fall, and there is a risk that you will not get back the money you invested.

Conflicts of interest:
The author may hold positions in the investment products mentioned. The author does not own positions in the underlying investment product exceeding 0.5% of its market capitalisation, save as otherwise declared. The author is not permitted to trade the mentioned investment products within the first 24 hours after the publication of this article.

Saxo maintains partnerships with companies that compensate Saxo for promotional activities conducted on its platform. Additionally, Saxo has agreements with certain partners who provide retrocession contingent upon clients purchasing specific investment products offered by these partners. While Saxo receives compensation from these partnerships, all content is conducted with the intention of providing clients with valuable options and information.

Publication details:
If any listed companies are the subject of the material, the content has not been submitted to the companies in question prior to publication.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo Markets
88 Market Street
CapitaSpring #31-01
Singapore 048948

Contact Saxo

Singapore
Singapore

Saxo Capital Markets Pte Ltd ('Saxo Markets') is a company authorised and regulated by the Monetary Authority of Singapore (MAS) [Co. Reg. No.: 200601141M ] and is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms & Risk Warning to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Saxo is part of the J. Safra Sarasin Group.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as Margin FX products may result in your losses exceeding your initial deposits. Saxo Markets does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Markets does not take into account an individual’s needs, objectives or financial situation.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-sg/about-us/awards.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website are not intended for residents of the United States, Malaysia and Japan. Please click here to view our full disclaimer.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.